Start here if you're new
what it is
Exelixis sells cancer drugs today and uses that cash to build more cancer drugs for tomorrow.
how it gets paid
Last year Exelixis made $2.3B in revenue. cabometyx product sales was the main engine at $1.84B, or 79% of sales.
why it's growing
Revenue grew 7.0% last year. Quarterly revenue jumped to $1.7 billion, up 188% vs. prior year, while full-year revenue reached $2.3 billion, up 7.0%.
what just happened
Exelixis posted Q4 EPS of $0.94, beating the $0.60 estimate by 56.7%.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
40/100 earnings predictability — expect surprises
14.3x trailing p/e — the market's not buying it — or you found a deal
50.0% return on capital — every dollar works hard here
xvary composite: 66/100 — average
What they do
Exelixis sells cancer drugs today and uses that cash to build more cancer drugs for tomorrow.
This company already has a real cash engine. Operating margin was 37.6% and return on capital hit 50.0%, which means each dollar invested throws off $0.50 in profit. In biotech, where many peers burn cash for years, Exelixis gets paid now while it builds the pipeline, and that gives you time instead of panic.
How they make money
$2.3B
annual revenue · their business grew +7.0% last year
cabometyx product sales
$1.84B
+8.0%
collaboration revenue
$0.42B
+2.0%
license revenue
$0.04B
flat
royalties and other
$0.02B
+10.0%
The products that matter
commercial oncology drug
Cabometyx
$2.3B revenue base
the current business was built around this franchise in kidney, liver, and thyroid cancers. If Cabometyx keeps holding up, the rest of the story gets time.
core franchise
pre-commercial oncology pipeline
Clinical pipeline
$700M pipeline budget
this is the second-act bet. A $700M budget matters because a one-drug story eventually needs another source of growth.
future growth
label expansion strategy
Indication expansion
kidney, liver, thyroid
every approved use extends the life of the core franchise. That is cheaper than building a new blockbuster from zero.
franchise extension
Key numbers
$3.0B
2029 revenue
That estimate implies the company still has a path to grow from today's $2.3 billion revenue base by about $700 million.
37.6%
operating margin
Operating margin → the share of sales left after running the business → so what: Exelixis keeps about $0.38 from each $1 of revenue before taxes and interest.
50.0%
return on capital
Return on capital → profit earned on money invested → so what: this is an unusually efficient biotech, not a cash incinerator.
14.3x
trailing P/E
P/E → stock price divided by last 12 months of earnings → so what: you are paying 14.3 times profits for a business with projected sales growth of 9.5%.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 45 / 100
- net profit margin 43.5% — keeps 44 cents of every dollar in revenue
- return on equity 50% — $0.50 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in EXEL 3 years ago → it's now worth $24,830.
The index would have given you $13,880.
source: institutional data · total return
What just happened
beat estimates
Exelixis posted Q4 EPS of $0.94, beating the $0.60 estimate by 56.7%.
Quarterly revenue jumped to $1.7 billion, up 188% vs. prior year, while full-year revenue reached $2.3 billion, up 7.0%. The quiet part is simple: cost discipline and a durable cabozantinib revenue stream did the heavy lifting.
$1.7B
revenue
$0.94
eps
37.6%
gross margin
the number that mattered
The 56.7% EPS beat matters most because it shows Exelixis is converting revenue into profit faster than analysts expected.
-
exelixis reported 2025 fourth-quarter and full-year results.during the december and year-end periods, revenues increased at a single-digit clip, to $598.7 million and $2.32 billion, respectively. earnings per share registered at $0.94 and $3.08, respectively, for the three- and 12-month periods. (our earnings presentation is on a non-gaap basis starting in 2025) the top-line momentum was driven by increased patient adoption of existing therapies. the build-out of the oncology franchise under the cabozantinib compound continues to gain traction within the medical community.
-
most recently, exelixis entered the neuroendocrine tumors and gastrointestinal cancer markets.the cabo name is approved and marketed under different labels for various types of cancer-related illnesses, including medullary thyroid cancer (cometriq) and renal cell carcinoma (cabometyx).
-
adjusted earnings benefited from the healthy revenue stream and cost-disciplined spending practices, including lower research costs and a 6% reduction in the workforce.
-
the outlook for 2026 and 2027 is upbeat.over this year and next, revenues and share earnings are expected to increase at a double-digit annual pace.
-
as mentioned above, new cancer arenas ought to allow exelixis to increase its addressable markets.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is Cabometyx concentration.
med
one franchise carries the story
The current $2.3B revenue base was built around Cabometyx. That is great until competition, pricing pressure, or clinical setbacks hit the same franchise all at once.
If the core drug stumbles, the impact lands on the entire business rather than a side segment.
med
the $700M pipeline budget has to buy a second act
Exelixis can afford to spend, but spending is not the same thing as producing another commercial engine. Pipeline work matters more here because diversification is still incomplete.
If pipeline investment fails to create another marketed asset, the stock stays trapped in a one-drug valuation box.
med
expectation risk is real
Earnings predictability is only 40/100 and price stability is 45/100. In human terms: the long-term story can stay intact while the stock still reacts badly to a noisy quarter.
That setup can compress the multiple fast, especially with shares already near the top of the 52-week range.
Together, these risks sit against an $11B equity value supported by $2.3B in revenue and one commercial franchise.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
Cabometyx revenue durability
One drug built the current $2.3B business. As long as that base keeps growing, the thesis has oxygen.
earnings
next quarterly print
With earnings predictability at 40/100, each report matters more here than it does in steadier large caps.
flow
institutional buying versus selling
295 buyers versus 320 sellers in 3Q2025 is a mild negative. Watch whether that gap narrows or widens.
risk
pipeline diversification
A $700M pipeline budget is large enough to matter. You need evidence it becomes a second growth engine, not just a recurring expense line.
Analyst rankings
earnings predictability
40 / 100
in human-speak, analysts think the core franchise is real but the quarter-to-quarter path can still get messy.
risk rank
3
Safer than 50% of stocks. Not a bunker, not a disaster.
price stability
45 / 100
This stock can move around even when the business stays profitable. Welcome to biotech with concentration risk.
source: institutional data
Institutional activity
295 buyers vs. 320 sellers in 3q2025. total institutional holdings: 0.3B shares.
source: institutional data
Price targets
3-5 year target range
$33
$83
$44
current price
$58
target midpoint · +32% from current · 3-5yr high: $85 (+95% · 18% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive